-       Report 
   - October 2022
    -  113 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - August 2022
    -  120 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - June 2022
    -  207 Pages 
    Global
   
   From       €2359EUR$2,625USD£2,069GBP 
      €4719EUR$5,250USD£4,138GBP 
                -       Report 
   - April 2023
    -  111 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - May 2024
    -  130 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                 -       Report 
   - February 2025
    -  85 Pages 
    India
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - October 2024
    -  87 Pages 
    Spain
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - September 2024
    -  82 Pages 
    Japan
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - August 2024
    -  85 Pages 
    India
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - August 2024
    -  82 Pages 
    Japan
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - July 2024
    -  185 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - May 2024
    -  184 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - May 2024
    -  184 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - February 2024
    -  170 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - November 2023
    -  90 Pages 
    France
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - November 2023
    -  81 Pages 
    Germany
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - November 2023
    -  171 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - October 2023
    -  81 Pages 
    Japan
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - March 2023
    -  117 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - December 2022
    -  111 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
             
         Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a    relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less   Read more